• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    9/23/24 8:13:02 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care
    Get the next $STSS alert in real time by email
    false 0001737995 0001737995 2024-09-20 2024-09-20 0001737995 STSS:CommonStock0.0001ParValueMember 2024-09-20 2024-09-20 0001737995 STSS:CommonStockPurchaseWarrantsMember 2024-09-20 2024-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): September 20, 2024

     

    Sharps Technology, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada

     

    (State or Other Jurisdiction of Incorporation)

     

    001-41355   82-3751728

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

     

    105 Maxess Road, Melville, New York 11747

     

    (Address of Principal Executive Offices)

     

    (631) 574 -4436

    (Registrant’s Telephone Number, Including Area Code)

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   STSS   NASDAQ Capital Market
    Common Stock Purchase Warrants   STSSW   NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    Securities Purchase Agreement

     

    On September 20, 2024, Sharps Technology, Inc., (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) and Senior Secured Note (the “Note”) for an aggregate principal amount of $4,375,000.00, with certain purchasers (the “Purchasers”), for the issuance of approximately 5,700,006 unregistered shares of the Company’s Common Stock or pre-funded warrants (the “Pre-Funded Warrants”) in lieu of shares of Common Stock. The Pre-Funded Warrants will be immediately exercisable, at an exercise price of $0.0001, subject to registration, and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of shares of Common Stock in the offering will be decreased on a one-for-one basis. The aggregate gross proceeds to the Company were approximately $3.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

     

    Registration Rights Agreement

     

    In connection with the Securities Purchase Agreement and Note, the Company entered into a Registration Rights Agreement with the Purchasers (the “Registration Rights Agreement”), requiring the Company to file a resale registration statement (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “Commission”) to register the unregistered shares of Common Stock and shares of Common Stock underlying the Pre-Funded Warrants within forty-five (45) calendar days following the filing date, which is thirty (30) days after the closing date (or, in the event of a full review by the Commission, seventy-five (75) calendar days following the filing date) and with respect to any additional Registration Statements which may be required pursuant to applicable sections of the Registration Rights Agreement, forty-five (45) calendar days following the date on which an additional Registration Statement is required to be filed thereunder (or, in the event of a full review by the Commission, seventy-five (75) calendar days following the date such additional Registration Statement is required to be filed thereunder); provided, however, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the effectiveness date as to such Registration Statement shall be the fifth (5th) trading day following the date on which the Company is so notified if such date precedes the dates otherwise required above; and provided, further, if such effectiveness date falls on a day that is not a trading day, then the effectiveness date shall be the next succeeding trading day. The Company will be obligated to pay certain liquidated damages to the Purchasers if the Company fails to file the Registration Statement when required, fails to cause the Registration Statement to be declared effective by the Commission when required, of if the Company fails to maintain the effectiveness of the Registration Statement.

     

    Placement Agent Agreement

     

    Aegis Capital Corp. (“Aegis”) acted as the exclusive placement agent in connection with the Securities Purchase Agreement and the Note under a Placement Agent Agreement (the “Placement Agent Agreement”), dated September 20, 2024, between the Company and Aegis. Pursuant to the Placement Agent Agreement, Aegis was paid a commission equal to eight percent (8.0%) of the gross proceeds received by the Company from the Securities Purchase Agreement and Note. The Company reimbursed Aegis $80,000 for certain fees and expenses incurred by them, including attorney fees. The Company also agreed to pay Aegis a non-accountable expense allowance equal to two percent (2.0%) of the Placement.

     

    The Securities Purchase Agreement, the Note, the Registration Rights Agreement, the Placement Agent Agreement and the Pre-Funded Warrant are filed as Exhibits 10.1, 10.2, 10.3 and 10.4, and 10.5 respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The above descriptions of the terms of the agreements are qualified in their entirety by reference to such exhibits.

     

     
     

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    The applicable information related to the Securities Purchase Agreement and the Note presented in Item 1.01 of this Current Report is incorporated by reference in this Item 3.02. The securities will be issued without prior registration in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D thereunder. In connection with the Purchasers’ execution of the Securities Purchase Agreement and the Note, the Purchasers represented to us that they are each an “accredited investor” as defined in Regulation D of the Securities Act and that the securities to be purchased by them will be acquired solely for their own account and not with a view to or for distributing or reselling such securities or any part thereof in violation of the Securities Act or any applicable state securities law. Such securities shall not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements and certificates evidencing such shares of common stock contain a legend stating the same.

     

    Item 8.01. Other Events

     

    Press Release

     

    On September 23, 2024, the Company issued a press release announcing the pricing of the offering. A copy of the pricing press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01 Exhibit Index

     

    10.1 Form of Securities Purchase Agreement
    10.2 Form of Senior Secured Note
    10.3 Form of Registration Rights Agreement
    10.4 Form of the Placement Agent Agreement
    10.5 Form of the Warrant
    99.1 Pricing Press Release dated September 23, 2024
    104 Cover Page Interactive Data File (formatted as Inline XBRL)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 23, 2024

     

    SHARPS TECHNOLOGY, INC.  
       
    /s/ Robert Hayes  
    Robert Hayes  
    Chief Executive Officer  

     

     

     

    Get the next $STSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sharps Technology and BitGo Announce Collaboration to Advance Solana Treasury Strategy

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company") (NASDAQ:STSS), a medical device company with a Solana (SOL) digital asset treasury strategy, and BitGo Bank & Trust, National Association ("BitGo"), the digital asset infrastructure company, today announced a strategic collaboration under which STSS will expand and further institutionalize its Solana treasury strategy through BitGo's services. As part of this arrangement, STSS intends to utilize BitGo's institutional-grade qualified custody through its OCC regulated entity, BitGo Bank & Trust, National Association. In addition, STSS intends to leverage BitGo's Solana staking validator to earn com

    2/5/26 7:00:00 AM ET
    $BTGO
    $STSS
    Finance: Consumer Services
    Finance
    Medical/Dental Instruments
    Health Care

    Sharps Technology Reports Strong Solana Staking Income

    NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. ("STSS" or the "Company"), a medical device company implementing a Solana-based digital asset treasury strategy, today issued an update on its treasury and recent operational highlights. Treasury Updates Staking: Since inception, STSS's validator partners have generated ~7% gross annual percentage yield (APY) before fees, outperforming the Solana network average. Nearly all of the Company's SOL holdings are currently staked.Balance Sheet: STSS continues to maintain sufficient operating capital and has no corporate debt. Recent Operational Highlights In January, STSS announced a lock-up agreement with its Strategic Advi

    1/26/26 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sichenzia Ross Ference Carmel LLP Achieves Firm Record Advising on Over 170 Transactions Totaling Over $14 Billion in 2025

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference Carmel LLP ("SRFC") reported that in 2025 it advised on over 170 announced transactions, with the total value of these transactions exceeding $14 billion, far surpassing the firm's strong performance in 2024. The transactions, on behalf of various market participants, such as issuers, underwriters and investors, included initial public offerings, secondary public offerings, registered direct offerings, private placements, mergers, acquisitions and cryptocurrency transactions. In October of 2025, for the fifth consecutive quarter, SRFC was ranked first in the nation for issuer counsel among securities law firms in Placement

    1/20/26 8:00:00 AM ET
    $EMIS
    $NCRA
    $SOUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Farming/Seeds/Milling
    Consumer Staples

    $STSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Sharps Technology Inc.

    SCHEDULE 13D - Sharps Technology Inc. (0001737995) (Subject)

    2/13/26 4:15:01 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Sharps Technology Inc.

    EFFECT - Sharps Technology Inc. (0001737995) (Filer)

    2/2/26 12:15:19 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sharps Technology Inc.

    SCHEDULE 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    1/23/26 6:09:54 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Falconx Holdings Ltd sold $1,490,755 worth of shares (769,320 units at $1.94) and exercised 461,538 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:45:04 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Falconx Holdings Ltd claimed ownership of 769,230 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:10:05 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Large owner Saba Capital Management, L.P. sold $86,371 worth of shares (37,182 units at $2.32) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    1/20/26 5:55:14 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Financials

    Live finance-specific insights

    View All

    Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Funded from the Company's recent PIPE equity raise, Sharps Technology now holds over 2 million SOL, creating a SOL treasury currently valued north of $400M. Sharps Technology intends to provide regular updates on its SOL holdings and performan

    9/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

    6/7/24 9:00:00 AM ET
    $SNGX
    $STSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip

    9/29/23 9:00:00 AM ET
    $AREC
    $RVPH
    $STSS
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $STSS
    Leadership Updates

    Live Leadership Updates

    View All

    Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

    NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ:STSS) (NASDAQ:STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics partnerships, along with a developing alliance with Roncadelle Operations, a driving force in the development of safe, novel medical drug delivery devices, would combine the strengths and capabilities of the two companies to develop, market and distribute unique dru

    2/16/24 2:42:54 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales

    Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the appointment of Ben Scheu as Senior Director of Sales to lead commercial operations as the Company prepares to launch products to the market.

    7/12/23 8:33:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Sharps Technology Appoints Justin Page as Vice President of Technical Operations

    NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the "Company", "Sharps") (NASDAQ: "STSS" and "STSSW"), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, appoints Justin Page as Vice President of Technical Operations. In his role, Mr. Page will be responsible for managing all aspects of Sharps' engineering operations. His primary focus will be to provide the leadership and technical expertise to support the prefillable syringe collaboration with Nephron Pharmaceuticals at the InjectEZ facility. These efforts will include the support for the injection molding of the specialty components and the high speed assembl

    2/9/23 9:21:23 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $STSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    10/9/24 9:01:14 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sharps Technology Inc.

    SC 13G - Sharps Technology Inc. (0001737995) (Subject)

    2/14/24 11:14:11 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care